We assessed the pattern of use and the effectiveness of antithrombotic therapy in a cohort of high-risk elderly patients hospitalized for atrial fibrillation, with data derived from prescription, hospitalization, and mortality databases from 3 linked registries. Results showed that antithrombotic therapy was underused, even in patients with no comorbid conditions. In addition, patients exposed to antithrombotic therapy had a significantly lower mortality rate. The collection of epidemiological data by record linkage represents a flexible and readily available tool for monitoring and improving routine clinical care.
For healthcare executives at all levels, addressing burnout is an urgent priority, one directly impacting their overall mission of improving quality of care and patient experience as well as retaining physicians and advanced practitioners.
In a case-control substudy of the Veterans Affairs High-Density Lipoprotein Intervention Trial, therapy with gemfibrozil was shown to reduce the total number of low-density lipoprotein (LDL) particles, especially small, more oxidizable LDL particles, which was associated with a reduced risk of coronary heart disease (CHD) events. Gemfibrozil also increased small-sized high-density lipoprotein particle numbers, which also correlated with a decrease in CHD events. Notably, these changes in particle numbers were not associated with significant changes in lipoprotein cholesterol concentrations, which current guidelines have made the principal target of lipid therapy.
Telehealth capabilities are crucial during the COVID-19 pandemic.
Prebiotics and probiotics have been discussed frequently in the media for supposedly improving overall health, especially diseases related to the gut. However, the evidence on the efficacy and use of these dietary supplements is rather complicated.
From a cliffside castillo to a trio of eco-adventure parks, the 85-mile stretch along Mexico's Caribbean coast offers a wide range of fun in the sun for adventurous travelers, and luxurious splendor for those looking to get away from it all.
The last several years have witnessed a heightened interest in the metabolic syndrome, as it has become a health issue of epidemic proportions. Several metabolic abnormalities emerge as key players in the pathogenesis of the syndrome, including insulin resistance, obesity, and inflammation. Individuals with the metabolic syndrome are at increased risk for a variety of clinical conditions, some with serious health implications, particularly diabetes and cardiovascular disease. Treatment should address the causal mediators of the syndrome, such as obesity or insulin resistance. Lifestyle modification is one of the most successful treatments for the prevention of diabetes. Pharmacotherapy for dyslipidemia or hypertension can help prevent cardiovascular complications and the development of diabetes in those at risk.
Cardiovascular drugs affect women differently than they do men because of differences in pharmacokinetics, pharmacodynamics, and physiology. Results of recent studies on the use of cardiovascular agents in women are presented, with an emphasis on the need to include an appropriate proportion of women in future studies, to adapt the dosage to the weight of the patient, and to incorporate hormonal aspects into the analysis.
The January issue of OBTN featured highlights from the 32nd Annual San Antonio Breast Cancer Symposium (SABCS). We wrap up our SABCS coverage this month with interviews on denosumab with Alison Stopeck, MD, associate professor of medicine at the University of Arizona and director of the Clinical Breast Cancer Program at the Arizona Cancer Center; oral bisphosphonates with Rowan T.Chlebowski, MD, PhD, professor and chief of the Los Angeles Biomedical Research Institute at Harbor-University of California, Los Angeles Medical Center; and adjuvant chemotherapy�induced alopecia with Hugues Bourgeois, MD, Centre Jean Bernard in Lemans, France.
We performed a meta-analysis of the effect of long-term treatment with antiarrhythmic drugs for the prevention of recurrent atrial fibrillation after conversion to sinus rhythm. We found that several class IA, IC, and III drugs are effective in maintaining sinus rhythm, but virtually all of them increase adverse effects, including proarrhythmia. In addition, class IA drugs are associated with increased mortality. The final risk-benefit ratio of antiarrhythmic drugs on clinically relevant outcomes is still unclear.
Researchers suggest that monitoring for the loss of CD62L expression on CD4+ T cells is a biomarker for risk assessment in patients treated with natalizumab who may develop PML, since other treatments do not show this pattern of C62L loss of expression.
How do I loathe EHRs? Let me count the ways...
Anil Asgaonkar, MD, provides an overview of the signs, symptoms, and causes that are frequently associated with hyponatremia, and outlines several standard treatment approaches.
We examined the prevalence and risks associated with undiagnosed diabetes mellitus among more than 7000 patients who had undergone coronary artery bypass graft surgery. At the perioperative and postoperative stages, patients with undiagnosed diabetes showed a significantly higher morbidity and mortality rate.
Providers should be aware that periodontal disease may hinder the efficacy of blood pressure medication.